Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  102,009 results for ""Tazobactam""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022-2024: results from the CLEAR registry.

  • Authors : Zhanel GG; Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.; Dhami R

Subjects: Cephalosporins*/Cephalosporins*/Cephalosporins*/administration & dosage ; Cephalosporins*/Cephalosporins*/Cephalosporins*/pharmacology ; Healthcare-Associated Pneumonia*/Healthcare-Associated Pneumonia*/Healthcare-Associated Pneumonia*/drug therapy

  • Source: Expert review of anti-infective therapy [Expert Rev Anti Infect Ther] 2024 Dec; Vol. 22 (12), pp. 1221-1228. Date of Electronic Publication: 2024 Sep 26.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101181284 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Effectiveness and safety of Ceftolozane/Tazobactam administered in continuous infusion through elastomeric pumps in OPAT regimen: a case series.

  • Authors : Giuliano G; UOC Malattie Infettive, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.; Dipartimento di Biotecnologie Mediche, Università degli Studi di Siena, Siena, Italy.

Subjects: Anti-Bacterial Agents*/Anti-Bacterial Agents*/Anti-Bacterial Agents*/administration & dosage ; Anti-Bacterial Agents*/Anti-Bacterial Agents*/Anti-Bacterial Agents*/adverse effects ; Anti-Bacterial Agents*/Anti-Bacterial Agents*/Anti-Bacterial Agents*/therapeutic use

  • Source: Infectious diseases (London, England) [Infect Dis (Lond)] 2024 Oct; Vol. 56 (10), pp. 887-893. Date of Electronic Publication: 2024 Sep 23.Publisher: Informa Healthcare Country of Publication: England NLM ID: 101650235 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Effect of incremental tazobactam concentrations on the bactericidal activity of piperacillin against ESBL-producing enterobacterales clinical isolates causing bacteraemia.

  • Authors : Palombo M; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Gatti M

Subjects: Anti-Bacterial Agents*/Anti-Bacterial Agents*/Anti-Bacterial Agents*/pharmacology ; Bacteremia*/Bacteremia*/Bacteremia*/microbiology ; beta-Lactamases*/beta-Lactamases*/beta-Lactamases*/metabolism

  • Source: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology [Eur J Clin Microbiol Infect Dis] 2024 Sep; Vol. 43Publisher: Springer Country of Publication: Germany NLM ID: 8804297 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1435-4373

Record details

Read More Add to Saved list
×
Academic Journal

The synergistic effect between phages and Ceftolozane/Tazobactam in Pseudomonas aeruginosa endotracheal tube biofilm.

  • Authors : Oliveira VC; Department of Dental Materials and Prostheses, School of Dentistry of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.; Human Exposome and Infectious Diseases Network - HEID, School of Nursing of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.

Subjects: Biofilms*/Biofilms*/Biofilms*/drug effects ; Pseudomonas aeruginosa*/Pseudomonas aeruginosa*/Pseudomonas aeruginosa*/virology ; Pseudomonas aeruginosa*/Pseudomonas aeruginosa*/Pseudomonas aeruginosa*/drug effects

  • Source: Emerging microbes & infections [Emerg Microbes Infect] 2024 Dec; Vol. 13 (1), pp. 2420737. Date of Electronic Publication: 2024 Nov 17.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101594885 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Molecular characterization of clinically isolated Pseudomonas aeruginosa with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021.

  • Authors : Li H; IHMA, Schaumburg, Illinois, USA.; Oliver A

Subjects: Ceftazidime*/Ceftazidime*/Ceftazidime*/pharmacology ; Azabicyclo Compounds*/Azabicyclo Compounds*/Azabicyclo Compounds*/pharmacology ; Drug Combinations*

  • Source: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2024 Oct 08; Vol. 68 (10), pp. e0067024. Date of Electronic Publication: 2024 Sep 10.Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam.

  • Authors : Hareza DA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Cosgrove SE

Subjects: Ceftazidime*/Ceftazidime*/Ceftazidime*/therapeutic use ; Ceftazidime*/Ceftazidime*/Ceftazidime*/pharmacology ; Cephalosporins*/Cephalosporins*/Cephalosporins*/therapeutic use

  • Source: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2024 Oct 08; Vol. 68 (10), pp. e0090724. Date of Electronic Publication: 2024 Sep 04.Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Differential frequency of persister cells in clinically derived isolates of Pseudomonas aeruginosa after exposure to cefiderocol and ceftolozane/tazobactam.

  • Authors : Fouad A; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.; Nicolau SE

Subjects: Pseudomonas aeruginosa*/Pseudomonas aeruginosa*/Pseudomonas aeruginosa*/drug effects ; Pseudomonas aeruginosa*/Pseudomonas aeruginosa*/Pseudomonas aeruginosa*/isolation & purification ; Cephalosporins*/Cephalosporins*/Cephalosporins*/pharmacology

  • Source: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2024 Dec 02; Vol. 79 (12), pp. 3236-3242.Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa.

  • Authors : Lodise TP; Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY, USA.; Obi EN

Subjects: Drug Combinations* ; Cephalosporins*/Cephalosporins*/Cephalosporins*/therapeutic use ; Ceftazidime*/Ceftazidime*/Ceftazidime*/therapeutic use

  • Source: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2024 Nov 04; Vol. 79 (11), pp. 2954-2964.Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.

  • Authors : Buyukyanbolu E; Department of Medical Microbiology, Health Sciences University Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. .; Center for Anti-Infective Research & Development, Hartford Hospital, 80 Seymour Street, Hartford, 06102, CT, USA. .

Subjects: Drug Combinations* ; Cephalosporins*/Cephalosporins*/Cephalosporins*/pharmacology ; Ceftazidime*/Ceftazidime*/Ceftazidime*/pharmacology

  • Source: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology [Eur J Clin Microbiol Infect Dis] 2024 Sep; Vol. 43Publisher: Springer Country of Publication: Germany NLM ID: 8804297 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1435-4373

Record details

Read More Add to Saved list
×
Academic Journal

In vitro activity of ceftolozane/tazobactam against Gram-negative bacilli isolated from pediatric patients: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2021, China.

  • Authors : Mu X; Department of Infectious Diseases, Sir Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.; Fu Y

Subjects: Cephalosporins*/Cephalosporins*/Cephalosporins*/pharmacology ; Tazobactam*/Tazobactam*/Tazobactam*/pharmacology ; Microbial Sensitivity Tests*

  • Source: Journal of global antimicrobial resistance [J Glob Antimicrob Resist] 2024 Sep; Vol. 38, pp. 216-222. Date of Electronic Publication: 2024 Jun 21.Publisher: Published by Elsevier Ltd. on behalf of International Society of Chemotherapy for Infection and Cancer Country of Publication: Netherlands NLM ID:

Record details

Read More Add to Saved list
×
  • 1-10 of  102,009 results for ""Tazobactam""